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Abstract
Background: Mitochondrial dysfunction may represent a pathogenic factor in Huntington disease (HD). Physical
exercise leads to enhanced mitochondrial function in healthy participants. However, data on effects of physical
exercise on HD skeletal muscle remains scarce. We aimed at investigating adaptations of the skeletal muscle
mitochondria to endurance training in HD patients.
Methods: Thirteen HD patients and 11 healthy controls completed 26 weeks of endurance training. Before and
after the training phase muscle biopsies were obtained from M. vastus lateralis. Mitochondrial respiratory chain
complex activities, mitochondrial respiratory capacity, capillarization, and muscle fiber type distribution were
determined from muscle samples.
Results: Citrate synthase activity increased during the training intervention in the whole cohort (P = 0.006). There
was no group x time interaction for citrate synthase activity during the training intervention (P = 0.522). Complex III
(P = 0.008), Complex V (P = 0.043), and succinate cytochrome c reductase (P = 0.008) activities increased in HD
patients and controls by endurance training. An increase in mass-specific mitochondrial respiratory capacity was
present in HD patients during the endurance training intervention. Overall capillary-to-fiber ratio increased in HD
patients by 8.4% and in healthy controls by 6.4% during the endurance training intervention.
Conclusions: Skeletal muscle mitochondria of HD patients are equally responsive to an endurance-training stimulus
as in healthy controls. Endurance training is a safe and feasible option to enhance indices of energy metabolism in
skeletal muscle of HD patients and may represent a potential therapeutic approach to delay the onset and/or
progression of muscular dysfunction.
Trial registration: ClinicalTrials.gov NCT01879267. Registered May 24, 2012.
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Background
Huntington disease (HD) is a hereditary, relentlessly
progressive neurodegenerative disorder caused by a
CAG triplet repeat expansion of the HTT gene encoding
the protein huntingtin. The disease is characterized by a
variety of symptoms, including motor, cognitive and
psychiatric dysfunctions [1]. Huntingtin is found in most
tissues, encompassing the central nervous system and
peripheral tissue, including skeletal muscle. So far, most
research has focused on the role of huntingtin in central
nervous tissue. Hence, its role and according patho-
mechanisms in peripheral tissue, as in skeletal muscle,
remains scarce. Previous studies reported mitochon-
drial abnormalities in skeletal muscle of HD patients
[2, 3] and diminished skeletal muscle mitochondrial
oxidative metabolism [4, 5]. In a previous study, we
showed that maximal oxidative phosphorylation capacity
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and mitochondrial respiratory capacity of complex I are
reduced in HD patients compared to healthy controls [6].
Collectively, these studies assume that mitochondrial dys-
function may represent a pathogenic factor in HD.
In a HD mouse model, physical activity attenuates the
onset of specific motor symptoms [7], improves coordin-
ation and gait function and retards disease progression
[8]. The underlying reasons for these improvements re-
main inconclusive, especially as predominantly neuronal
and cognitive mechanisms have been investigated [7, 8].
Thus, evidence for a positive effect of physical activity
on mitochondrial function in HD skeletal muscle is lack-
ing both in humans and animal models. In a recent pub-
lication, we showed that endurance exercise increased
peak oxygen uptake (V̇O2peak) to a similar extent in HD
patients and healthy controls [9]. In addition, in healthy
humans, endurance training is well known to improve
mitochondrial properties. Hence, endurance training
could potentially enhance physical performance as well
as oxidative capacity in HD patients.
In the present study, we aimed at investigating adapta-
tions of the skeletal muscle and mitochondria to endur-
ance training in HD patients. Based on our previous
results [6], we hypothesized that skeletal muscle mito-
chondrial function is impaired in HD patients, but that
it can be increased by endurance exercise to a similar
extent as in healthy controls.
Methods
Participants
Fifteen male HD patients and fifteen age-matched male
controls were included in the study. One HD patient
and three control participants prematurely finished the
study due to loss of motivation. The data of one HD pa-
tient were excluded from the analysis because he was di-
agnosed with leukemia during the training intervention.
In one control participant, the amount of tissue obtained
from biopsy was not sufficient for all analyses. Finally,
thirteen HD patients with a genetically verified diagnosis
of HD (age: 53.2 ± 8.8 years, height: 175 ± 5 cm, body
mass: 78.7 ± 13.0 kg, V̇O2peak: 36.1 ± 6.5 ml·min
−1·kg−1,
CAG repeats: 42.0 ± 2.3) and eleven control participants
(age: 49.7 ± 6.8 years, height: 178 ± 4 cm, body mass:
84.6 ± 13.6 kg, V̇O2peak: 36.5 ± 6.0 ml·min
−1·kg−1) were
included in the analyses. There were no statistically sig-
nificant differences between groups for age, height, body
mass, and V̇O2peak. In the Unified Huntington Disease
Rating Scale, HD patients had the following scores: total
motor score 18.0 ± 8.7, verbal fluency 27.8 ± 10.7, symbol
digit modalities 39.3 ± 8.7, Stroop test color 54.1 ± 15.5,
Stroop test word 79.6 ± 16.7, Stroop test interference
34.9 ± 11.2, total behaviour score 10.3 ± 12.0, functional
checklist score 23.1 ± 2.3, independence scale 91.5 ±
8.5%, total functional capacity 11.0 ± 2.2. These values
are compatible with a mostly low disease severity. After
completing a routine health questionnaire, the partici-
pants were informed about the applied procedures and
the associated risks. Participants provided written in-
formed consent for participation in this study. All exper-
iments were approved by the local ethics committee and
the study was performed in accordance with the ethical
standards laid down in the Declarations of Helsinki for
human experimentation. Medication was protocolled
during the entire study period. None of the HD patients
took drugs that enhance muscle mitochondrial function.
Experimental design
The natural course of the disease was observed in HD
patients for 26 weeks, before endurance training started.
Thereafter, HD patients and healthy controls conducted
an endurance training intervention for a total of
26 weeks. In HD patients, before the observation phase
of the natural disease progression, a baseline percutan-
eous muscle biopsy was obtained from M. vastus latera-
lis. A second biopsy was obtained from HD patients
before the training intervention and a final third biopsy
directly after the training intervention. In healthy con-
trols, only two biopsies (before and after the training
intervention) were obtained. Muscle samples were used
for histochemistry, mitochondrial DNA quantification,
spectrophotometric analyses of the respiratory transport
chain and mitochondrial respiration measurements.
Exercise intervention
The exercise intervention was divided into three training
phases that were interspersed with 1-week rest periods.
The rest periods served its role in supporting (psycho-
logical) recovery from the previous demanding training
phases. During the first 10 weeks, HD patients and
healthy controls followed a constant-load cycling proto-
col (30 min at a cycling power corresponding to 65%
V̇O2peak) three times a week. After the first rest period,
HD patients and healthy controls performed a high-
intensity interval training (4 × 4 min at 90–95% of peak
heart rate with 3 min low-intensity rest intervals at 70%
of peak heart rate, according to Helgerud et al. [10]) 3
times a week for the following 8 weeks. After the second
1-week rest period, a final 6-weeks endurance training
protocol consisting of two interval training sessions and
one constant-load training session per week [11] was
performed. To assure a sufficient training stimulus, cyc-
ling power was increased as soon as the participants’
heart rate fell below the target values.
Skeletal muscle biopsy
Before each biopsy, participants were tested for coagula-
tion abnormalities (Quick/INR, number of thrombo-
cytes). Skeletal muscle biopsies were obtained under
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standardized conditions from the M. vastus lateralis
upon local anesthesia with 1% lidocaine of the skin and
superficial muscle fascia, using the Bergström technique
with a needle modified for suction [12]. The biopsy was
immediately dissected macroscopically free of fat and
connective tissue and divided into sections for actual
measurement of mitochondrial respiratory capacity,
mitochondrial DNA quantification, spectrophotometrical
analysis and histochemistry. Skeletal muscle biopsies
were conducted before and after the training interven-
tion. In HD patients, an additional biopsy was obtained
at baseline.
Mitochondrial respiration measurements
In a subgroup of six HD patients, mitochondrial respiration
measurements were performed before and after the training
intervention. The preparation of the skeletal muscle tissue
and the titration protocol were conducted as described in
detail previously [13]. In summary, after mechanical muscle
fiber separation, chemical permeabilization in biopsy
preservation solution and washing in mitochondrial respir-
ation medium 05, muscle bundles were blotted dry and
measured for wet weight (ww) on a balance-controlled scale
(XS205 DualRange Analytical Balance, Mettler-Toledo AG,
Greifensee, Switzerland). Respiration measurements were
subsequently performed in mitochondrial respiration
medium 06. Oxygen consumption of the individual muscle
tissue was thereby measured at 37 °C using the high-
resolution Oxygraph-2 k (Oroboros, Innsbruck, Austria).
Experiments were performed as duplicates in a hyperoxyge-
nated environment in order to prevent any potential oxy-
gen diffusion limitation. Thereby, oxygen concentration
ranged between 200 and 450 nmol mL−1 within the cham-
bers. The respiratory measurement protocol was specific to
the analysis of individual aspects of respiratory capacity and
coupling control efficiency during several substrate states
induced via separate titrations. All titrations were added in
series as presented, whereby the concentrations of sub-
strates, uncouplers and inhibitors used were based on prior
experiments [14]. The titration protocol was modified from
previous protocols where they are described in detail [14].
Biochemical assays
Skeletal muscle homogenates were performed as de-
scribed previously [15, 16]. The activities of the individ-
ual respiratory chain complexes and the mitochondrial
matrix marker enzyme citrate synthase were measured
spectrophotometrically with an UV-1601 spectropho-
tometer (Shimadzu, Kyoto, Japan) using 1 ml sample cu-
vettes thermostatically maintained at 30 °C according to
Birch-Machin and Turnbull [17]. Values were estimated
by the difference in activity levels measured in the pres-
ence and absence of specific inhibitors and expressed as
ratios to the mitochondrial marker enzyme citrate
synthase (mU·mU−1 citrate synthase), which was deter-
mined as described [18].
Histochemistry
Tissue sections were cut at 12-μm thickness in a cryostat
maintained at −25 °C, and mounted on Fisherbrand
Superfrost/Plus microscope slides (Fisher Scientific,
Pittsburgh, PA, USA). The serial cryocut cross-sections
were stained using the myofibrillar adenosine tripho-
sphatase (mATPase) method at pH 4.6 as previously
described [19]. Muscle fibers were classified according to
their myosin heavy chain (MyHC) isoform into
MyHC-1, MyHC-2A and MyHC-2X. Per point in time,
479 ± 300 MyHC-1 fibers, 257 ± 136 MyHC-2A fibers,
and 94 ± 109 MyHC-2X fibers were counted for deter-
mination of muscle fiber type distribution. As marker
for muscle capillaries, the monoclonal mouse anti-
human CD31 endothelial antibody (DAKO, Carpin-
teria, CA, USA, 1:600 dilution) was used. Overall
capillary-to-fiber ratio was calculated by dividing the
number of CD31-positive structures by the number of
muscle fibers. On average, 159 ± 96 capillaries were
counted per point in time for the calculation of the
overall capillary-to-fiber ratio. We used the NIH
Image J Software (version 1.44o, National Institutes of
Health, Bethesda, MD, USA) for all fiber analyses.
Statistical analysis
Data are presented as mean ± SD. Normality of data was
visually ascertained by Q-Q-Plots. Analysis of variance
with repeated measures was performed to detect
changes between groups over time during the interven-
tion phase. To detect differences between baseline and
pre-training in the HD group, paired samples t-tests
were performed. SPSS statistical software (Version 24.0,
SPSS, Chicago, IL, USA) was used for all statistical ana-
lyses. A value of P < 0.05 was set as statistical
significance.
Results
Citrate synthase activity increased in the HD group by
18.9% and in the control group by 27.5% during the
training intervention (Table 1). There was a group effect
for citrate synthase activity, but no group x time inter-
action was present during the training phase (P = 0.522).
Absolute complex I activity decreased during the natural
observation period in HD patients by −15.6%. There was
no further decrease in absolute complex I activity during
the training intervention in HD patients (−0.7%).
Healthy controls had a significantly higher absolute
complex I activity as compared to HD patients. There
were time effects for absolute complex III, complex V
and succinate cytochrome c reductase (SCCR) activities
during the training intervention. Neither group nor
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group x time effects were present for these variables.
Complex I activity normalized to citrate synthase activity
decreased during the natural course observation phase in
HD patients by −15.6%. Moreover, there were significant
time effects for relative complex I (−16.2% and −22.5% for
the HD and control group, respectively) and complex II
(−13.6% and −1.3% for the HD and control group, respect-
ively) activities during the training intervention. HD pa-
tients exhibited significant higher relative complex V and
NADH cytochrome c reductase (NCCR) activities than
healthy controls. There were no group x time interactions
for all assessed relative variables (Table 1).
In the subgroup of six HD patients with mitochondrial
respiratory measurements, fatty acid oxidative capacity
(+38.7%), leak respiration without adenylates (+23.6%),
respiratory capacity of complex I (+43.2%), oxidative
phosphorylation capacity (+33.4%), maximum electron
transport chain capacity (+24.6%) and respiratory cap-
acity of complex IV (+23.4%) were increased after the
training intervention (Fig. 1a). After normalizing mito-
chondrial respiratory capacity to citrate synthase activity,
all respiratory states remained unaltered in response to
endurance training (Fig. 1b).
Muscle fiber type distribution remained constant
during the endurance training intervention in both
groups (Table 2). Additionally, there was no group ef-
fect for muscle fiber type distribution. There was also
no alteration in muscle fiber type distribution in the
HD group during the natural course observation
period. Overall capillary-to-fiber ratio remained con-
stant during the natural course observation period in
HD patients (P = 0.449). During the endurance training
intervention, overall capillary-to-fiber ratio increased by
8.4% in HD patients and by 6.4% in control participants
(Fig. 2). There was no group effect (P = 0.973) nor a group
x time interaction (P = 0.928) for the overall capillary-to-
fiber ratio.
Discussion
In this study, we showed that increases in mitochondrial
content and capillarization in response to prolonged en-
durance training is similar for HD patients and matched
healthy controls. Namely, after an endurance training
intervention, citrate synthase, complex III, complex V
and SCCR activities increased similarly in HD patients
and healthy controls. In addition, an increase in mass-
specific mitochondrial respiratory capacity was present
in HD patients during the endurance training interven-
tion. Furthermore, overall capillary-to-fiber ratio in-
creased in HD patients and healthy controls following
endurance training.
The most important aspect of the present study is the
similar responsiveness of the skeletal muscle of HD pa-
tients to an endurance training stimulus when compared
Table 1 Mitochondrial complex activities at baseline, pre-training and post-training in Huntington disease (HD) patients and healthy
controls
HD (n = 13) Controls (n = 11)
Baseline Pre-Training Post-Training Pre-Training Post-Training
Absolute values
Citrate synthase (mU·mU−1 Protein) 150 ± 42 141 ± 34 163 ± 47##, † 164 ± 65 198 ± 67##, †
Complex I (mU·mU−1 Protein) 35 ± 11 28 ± 9* 26 ± 7† 36 ± 15 33 ± 13†
Complex II (mU·mU−1 Protein) 40 ± 9 38 ± 11 37 ± 11 37 ± 14 44 ± 16
Complex III (mU·mU−1 Protein) 123 ± 35 114 ± 32 137 ± 51## 122 ± 46 154 ± 55##
Complex IV (mU·mU−1 Protein) 165 ± 39 151 ± 56 131 ± 47 142 ± 50 164 ± 51
Complex V (mU·mU−1 Protein) 75 ± 25 72 ± 24 91 ± 29# 69 ± 29 80 ± 26#
SCCR (mU·mU−1 Protein) 34 ± 11 35 ± 8 49 ± 25## 35 ± 14 46 ± 14##
NCCR (mU·mU−1 Protein) 28 ± 15 29 ± 12 35 ± 13 26 ± 11 30 ± 10
Relative values
Complex I (mU·mU−1 CS) 0.241 ± 0.044 0.201 ± 0.051* 0.164 ± 0.037### 0.225 ± 0.049 0.168 ± 0.044###
Complex II (mU·mU−1 CS) 0.271 ± 0.041 0.269 ± 0.059 0.227 ± 0.038# 0.232 ± 0.044 0.225 ± 0.043#
Complex III (mU·mU−1 CS) 0.837 ± 0.158 0.828 ± 0.203 0.846 ± 0.184 0.796 ± 0.087 0.779 ± 0.099
Complex IV (mU·mU−1 CS) 1.124 ± 0.191 1.067 ± 0.300 0.835 ± 0.246 0.871 ± 0.119 0.840 ± 0.133
Complex V (mU·mU−1 CS) 0.507 ± 0.155 0.522 ± 0.168 0.528 ± 0.109† 0.414 ± 0.074 0.400 ± 0.067†
SCCR (mU·mU−1 CS) 0.228 ± 0.056 0.253 ± 0.048 0.269 ± 0.095 0.215 ± 0.033 0.236 ± 0.034
NCCR (mU·mU−1 CS) 0.185 ± 0.094 0.209 ± 0.081 0.222 ± 0.120†† 0.145 ± 0.029 0.153 ± 0.016††
Values are mean ± SD. NCCR, NADH cytochrome c reductase, SCCR, succinate cytochrome c reductase. *P < 0.05, significant different to baseline; #P < 0.05, ##P <
0.01, ###P < 0.001, significant time effect; †P < 0.05, †P < 0.01, significant group effect
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to healthy controls. Evidence for this is that citrate syn-
thase activity significantly increased in both training
groups. Moreover, several mitochondrial complex activ-
ities increased (in absolute values), which is in line with
the increased mass-specific respiratory capacities of the
mitochondrial complexes. Altogether, these results im-
plicate that mitochondrial content was increased in re-
sponse to endurance training in HD patients as well as
in healthy controls. Increased citrate synthase activity is
a well-known adaptation to moderate-intensity continu-
ous training and/or high-intensity interval training in
healthy participants and patients within a wide variety of
diseases [20]. In addition, overall capillary-to-fiber ratio
increased similarly in HD patients and controls. These
findings are consistent with our previous result showing
that V̇O2peak is increased in HD patients following a
period of endurance training [9].
Our results emphasize that increasing mitochondrial bio-
genesis is possible in HD patients in response to endurance
training. Since post-training values of HD patients for cit-
rate synthase activity approached pre-training values of
healthy controls, it might be that life-long endurance
training in HD patients could have the potential to delay
mitochondrial dysfunction in skeletal muscle. The present
results expand the findings of pharmacological studies in
the HD mouse model aimed at delaying mitochondrial
alterations [21–23]. For instance, the pan-peroxisome
proliferator-activated receptor agonist bezafibrate prevented
structural abnormalities of mitochondria in HD mice
[21, 22]. Moreover, it is postulated that increasing
mitochondrial biogenesis does not only prevent mito-
chondrial dysfunction but also attenuates neurodegen-
eration and disease progression [24]. Therefore, an
elevation of mitochondrial biogenesis through endur-
ance training might be a promising therapeutic inter-
vention in HD patients.
When values for mitochondrial enzyme activities and mito-
chondrial respiratory capacities were normalized for citrate
synthase activities, no significant increases were observed.
These results indicate that an increase in mitochon-
drial content or quantity was present, but that intrinsic
mitochondrial function or quality remained constant.
Our finding is supported by a previous study investigat-
ing the effects of moderate intensity continuous
exercise or high-intensity interval training in healthy
participants [25]. Based on these observations, it has re-
cently been postulated that mitochondrial quality im-
provements do only occur once mitochondrial content
a
b
Fig. 1 Mass-specific mitochondrial (a) and mitochondrial-specific
(b) respiratory capacity (normalized to citrate synthase). Respiratory
capacities are presented for Huntington disease patients (n=6) before
training (white bars) and after the training intervention (black bars). LN, leak
respiration without adenylates; PETF, fatty acid oxidative capacity; PCI,
respiratory capacity of complex I; P, oxidative phosphorylation capacity; LOmy,
oligomycin-induced leak respiration; ETS, electron transport system capacity; PCII,
respiratory capacity of complex II; ROX, residual oxygen consumption; COX,
respiratory capacity of complex IV. Values are mean±SD. *P<0.05; **P<0.01,
significant differences between pre-training and post-training
Table 2 Muscle fiber type distribution and cross-sectional areas of muscle fibers at baseline, pre-training and post-training in
Huntington disease (HD) patients and healthy controls
HD patients (n = 13) Controls (n = 11)
Baseline Pre-Training Post-Training Pre-Training Post-Training
Muscle fiber type distribution
MyHC-1 (%) 59.0 ± 13.9 57.0 ± 13.8 60.2 ± 10.0 56.7 ± 9.7 53.5 ± 12.2
MyHC-2A (%) 33.3 ± 9.5 30.9 ± 10.6 32.5 ± 10.7 31.7 ± 7.5 34.9 ± 12.9
MyHC-2X (%) 7.8 ± 6.7 12.1 ± 10.0 7.3 ± 5.8 11.6 ± 10.0 11.6 ± 7.3
Values are mean ± SD. MyHC, myosin heavy chain
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has increased to the limit allowed by spatial constraints
of the muscle fibers [26].
HD patients exhibited lower citrate synthase and abso-
lute complex I activity when compared to their healthy
counterparts. The lower citrate synthase activity in con-
junction with similar relative enzyme activities indicated
that HD patients exhibited a lower mitochondrial
content but preserved mitochondrial quality when com-
pared to healthy controls. This finding is in line with a
previous finding of our group [6] and expands the
knowledge about mitochondrial dysfunction in HD pa-
tients. Up to date, it was reported that mitochondrial ab-
normalities are present in skeletal muscle of HD patients
[2, 3] and that some patients had diminished skeletal
muscle mitochondrial oxidative metabolism [4, 5].
Absolute and relative complex I activities decreased
during the natural course observation phase in HD
patients. Moreover, relative complex I and II activities
decreased during the training intervention in the entire
cohort. This observation might rely on two different fac-
tors. First, respiratory states of complex I and II normal-
ized for citrate synthase activity were not altered in the
subgroup of HD patients. Therefore, the discrepancy in
relative complex I and II activities measured by spectro-
photometry or mitochondrial respiration might be based
on methodological differences. The spectrophotometric
measurements reflect isolated respiratory chain complex
activities from muscle homogenates, while mitochon-
drial respiration measurements in permeabilized muscle
fibers measures oxygen consumption dependent on
different substrates. The latter procedure preserves
mitochondrial morphology and integrity, whereby the
examination of the intact mitochondrial network is
feasible [27]. Therefore, mitochondrial respiration mea-
surements might be considered as more accurate
measurements to assess in vivo mitochondrial function.
Second, associations between the degree of the disease
and complex I and II/III dysfunctions, assessed spectro-
photometrically, have been reported previously [2, 28].
Hence, it might be assumed that the HD patients of this
study, which exhibited mostly low disease severity, were
only slightly affected by these dysfunctions. Prolonged
disease duration and a higher disease severity might,
however, lead to lower complex activities and reduced
mitochondrial quality.
In contrast, complex V and NCCR activities normal-
ized to citrate synthase activity were higher in HD pa-
tients as compared to healthy controls. We can only
speculate about the underlying reasons for these elevated
activities. The elevated complex V activity might rely on
an increased substrate availability. Choreatic movements
in HD patients might elevate intracellular adenosine di-
phosphate (ADP) concentrations, whereby a higher
amount of substrate is available for adenosine triphos-
phate (ATP) synthase. In this regard, ADP availability
would be the rate-limiting step in healthy individuals
and would explain their lower complex V activity. In HD
patients, the higher relative NCCR activity and the ten-
dency for a higher relative SCCR activity indicate that
complex I and II are, at the current disease state, not
the rate-limiting steps in the respiratory transport
chain. Moreover, the (unknown) rate-limiting step be-
tween complex I or II and complex III is even im-
proved in HD patients compared to healthy controls.
This improvement in the rate-limiting step might rep-
resent an early onset compensation for the disease-
related dysfunctions in complex I and II/III activities,
as previously reported [2, 28].
Conclusions
In conclusion, skeletal muscle mitochondria of HD pa-
tients are equally responsive to a prolonged period of
endurance training as healthy controls. Moreover, be-
sides mitochondrial content, overall capillary-to-fiber ra-
tio increased similarly in HD patients and healthy
controls. In contrast, there were no alterations in muscle
fiber type distribution in both groups. Therefore, endur-
ance training is a safe and feasible option to enhance en-
ergy metabolism in skeletal muscle of HD patients and
may represent a potential therapeutic approach to delay
the onset or progression of muscular dysfunction.
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